safety and efficacy of intravenous trappsol cyclo (hpbcd) in niemann-pick type c patients

Conditions: Niemann-Pick Disease, Type C1

Summary: this research study is being conducted to find out whether trappsol® cyclo™, an experimental treatment for people with niemann-pick disease type c1 (npc-1) is safe at 3 different dose levels and what effects it has on people who have this condition. npc-1 is caused by a defect in a protein which is important for the transport of fatty substances like cholesterol out of cells. without this protein, fats build up in the cells ultimately leading to organ damage. the way in which this experimental treatment works is not fully understood but laboratory experiments have shown that it can potentially remove cholesterol build up from the cells in people who have npc-1. approximately 12 patients will be asked to take part in this research study for up to 56 weeks in total. recruitment is expected to take 9 months.patients who take part will receive treatment by an intravenous infusion every two weeks. the study will look at what the body does to the drug as well as what the drug does to the body by taking and examining blood and urine samples. samples of cerebrospinal fluid (csf) are also taken by lumbar puncture during and following the first treatment dose. patients will also have their hearing tested, be asked questions by their doctor as well completing questionnaires to help assess any changes in their condition during treatment. optional assessments patients can choose to take part in include liver biopsies, additional lumbar punctures for csf.examinations to see if the drug is affecting these. this study is being sponsored and funded by ctd holdings inc. it is planned to be run in the uk, italy, and sweden.

the planned study has been designed as a phase i/ii, double-blind, randomised, multi-centre, parallel group study based on information and data available from the administration of trappsol cyclo via compassionate/named patient use in patients with npc-1, and data on other cyclodextrin products in the scientific literature. the study is comprised of two stages. the primary objective of stage 1 is to compare the plasma pharmacokinetics of three different doses of iv trappsol cyclo in the prevention /delay of npc-1 progression.secondary objectives include investigation of the hydroxypropyl beta cyclodextrin (hp-β-cd) effect of three different doses of iv trappsol cyclo upon serum and lymphocytic markers of cholesterol metabolism (stages 1 and 2) and evaluation of concentrations in the cerebrospinal fluid (csf) following intravenous (iv) administration (stage 1), evaluation of the impact of treatment upon measures of neurological function including ataxia, aphasia and saccadic eye movements, and the impact of treatment upon behavioural aspects of npc-1 (stage 2). it is planned to recruit a total of 12 patients to the study. patients will be randomised 1:1:1 to one of the three dose levels (1500 mg/kg, 2000 mg/kg or 2500 mg/kg; four patients per dose level). treatment will be administered every two weeks by slow iv infusion at a concentration of 250 mg/ml over 8 hours. patients completing stage 1 of the study will continue into stage 2 and receive treatment for 48 weeks. patients who withdraw prior to completion of the initial pharmacokinetic (pk) and pharmacodynamics (pd) assessments will be replaced. the design of the proposed study thus enables early assessment of biochemical markers of response but allows for a sufficient dosing duration to enable the effectiveness of trappsol in npc-1 to be assessed. as miglustat is an approved treatment for npc-1 in the eu, with an established efficacy and safety profile, it would be unethical to exclude patients receiving miglustat therapy from the study, given that the study itself will also be conducted at sites in europe. however, it is planned to balance randomisation across the treatment groups for its use. the maximum dose proposed for this study is below the maximum dose for which long term clinical data is available in 2 patients (2800 mg/kg weekly for 3-5 years). although individual clinicians have not always utilised an escalating rate of infusion, the reports of infusion related reactions in three patients suggest that this is an appropriate clinical strategy to mitigate the risk of such events and is consistent with dosing administration for other therapeutic agents. in the proposed study, treatment will be administered less frequently than has been undertaken in compassionate use. this longer dosing interval is supported by nonclinical data comparing the metabolism of cholesterol in non-human species with that in man; although a once weekly dosing interval was initially studied in man based on data in the mouse, hp-β-cd cholesterol metabolism/turnover in the mouse is 13-fold higher than in man which, in npc-1, likely translates into a 13-fold slower accumulation of cholesterol in human cells compared with those of the mouse.therefore, it is theorised that, given the slower cholesterol metabolism in humans, the dosing interval could be much less frequent in man than in mouse; however, based on what is known about cholesterol metabolism in humans and the pharmacokinetic and pharmacodynamic effect of hp-β-cd in the mouse, a dosing interval of 2 weeks in man is likely to be well within the therapeutic dosing interval and also minimises the amount of infusions required to be administered.

Eligibility criteria:
inclusion criteria: 1. confirmed diagnosis of npc-1 defined as one of the following * two npc-1 mutations on genotyping * one npc-1 mutation and positive filipin staining (current or prior) * vertical supranuclear gaze palsy \[vsngp\] plus either ≥ one npc-1 mutation or positive filipin staining and no npc-2 mutations 2. nih npc severity score \<30 and with no more than 4 individual domains with a score ≥ 3. 3. age range: 2 years upwards * inclusion of the first three paediatric patients will be restricted to individuals aged ≥ 5 years. once the first three paediatric patients have safely completed stage 1, study entry will be open to all ages ≥2 years as per the protocol 4. negative pregnancy test for females of child bearing potential 5. written, informed consent - exclusion criteria: 1. the presence of npc-2 mutations on genotyping 2. previous receipt of cyclodextrin therapy 3. lanksy score \ 16. 4. inability to comply with the proposed protocol assessments 5. concurrent treatment with any type of cholesterol lowering agents such as statins, fibrates, ezetimibe 6. concurrent medical conditions representing a contraindication to any of the study medications 7. stage 3 renal impairment or worse as indicated by egfr\< 60ml/min using the mdrd equation 8. clinical evidence of acute liver disease including symptoms of jaundice or right upper quadrant pain or inr \>1. 8 9. involvement in another interventional clinical trial within the previous 6 months 10. weight \>100 kg 11. females of childbearing potential who are not willing to use a method of highly effective contraception (hormonal contraception, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner, or true abstinence) during the study and the follow-up period. true abstinence can only be in line with the preferred and usual lifestyle of the subject. periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a trial, and withdrawal are not acceptable methods of contraception. 12. females who are breastfeeding -